Standalone figures · ₹ crore
| ₹ Cr | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 540 | 520 | 618 | 555 | 610 | 551 | 556 | 499 | 522 | 554 | 606 | 583 | |
| COGS | 293 | 272 | 312 | 279 | 316 | 280 | 282 | 242 | 282 | 272 | 313 | 304 |
| Gross profit | 247 | 248 | 306 | 275 | 294 | 271 | 274 | 256 | 240 | 281 | 292 | 278 |
| 204 | 182 | 215 | 214 | 231 | 197 | 206 | 189 | 178 | 200 | 218 | 217 | |
| 43 | 66 | 91 | 61 | 63 | 74 | 68 | 67 | 62 | 81 | 74 | 61 | |
| OPM % | 8% | 12.6% | 14.7% | 11% | 10.3% | 13.5% | 12.2% | 13.5% | 11.9% | 14.7% | 12.3% | 10.5% |
| Depreciation | 21 | 21 | 21 | 20 | 22 | 21 | 22 | 22 | 22 | 22 | 25 | 26 |
| Interest | 40 | 44 | 47 | 47 | 50 | 34 | 29 | 30 | 29 | 27 | 27 | 29 |
| 22 | 3 | 30 | 12 | 24 | 2 | 12 | 2 | 14 | 103 | 4 | 78 | |
| Profit before tax | 4 | 4 | 53 | 6 | 14 | 21 | 28 | 16 | 25 | 135 | 27 | 85 |
| Tax | 3 | 1 | -1 | 2 | -1 | 6 | 12 | 3 | -7 | 13 | 10 | 12 |
| Tax % | 69.5% | 27.8% | -1.7% | 30.9% | -6.1% | 30.1% | 43.1% | 18.7% | -26.2% | 9.6% | 38.3% | 14% |
| 1 | 3 | 54 | 4 | 15 | 15 | 16 | 13 | 32 | 122 | 16 | 73 | |
| PAT margin % | 0.2% | 0.5% | 8.7% | 0.7% | 2.5% | 2.7% | 2.9% | 2.7% | 6.1% | 22% | 2.7% | 12.5% |
| EPS (₹) | 0.1 | 0.3 | 5.8 | 0.4 | 1.7 | 1.6 | 1.8 | 1.5 | 3.5 | 13.2 | 1.8 | 7.9 |
| Results filing | — | — | — | — | — | — | — | Results filing for Jun 2025 | Results filing for Sep 2025 | Results filing for Dec 2025 | Results filing for Mar 2026 | Results filing for Jun 2026 |
| vs same quarter last year | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % | +12.3% | +34.5% | +9.6% | +16.7% | +12.9% | +5.9% | -10% | -10.1% |
As reported in NSE results XBRL. Segment result is before tax and finance costs.
Latest reported period · 30 Sept 2024 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceutical business | 609.96 | 64.58 | — | 2,299.37 |
| Bio-pharmaceutical business | 0 | 0 | — | 0 |
₹ crore by quarter
| -14.4% |
| +0.5% |
| +9% |
| +16.9% |
| PAT YoY % | — | -79.7% | -14% | -51% | +1,096.1% | +488.2% | -69.9% | +240.6% | +109.3% | +715.9% | +1.4% | +446.3% |